Ouellet Véronique, Le Page Cécile, Madore Jason, Guyot Marie-Claude, Barrès Véronique, Lussier Christian, Tonin Patricia N, Provencher Diane M, Mes-Masson Anne-Marie
The Research Centre of the University of Montreal Teaching Hospital (CR-CHUM)/Montreal Cancer Institute, Montreal, Quebec, Canada.
Cancer. 2007 Jul 15;110(2):297-308. doi: 10.1002/cncr.22812.
In a previous microarray expression analysis, the authors identified candidate genes that were expressed differentially between ovarian tumors with low malignant potential and invasive serous epithelial ovarian tumors. Among them, the apoptosis-related candidate genes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), caspase 8 (CASP8), FLICE-inhibitory protein (FLIP), and cytochrome C (CYC) were identified.
For the current study, the authors conducted immunohistochemical analyses of a tissue array comprised of 235 serous tumors of different grades and stages to evaluate whether there was differential protein expression for these candidates and for the 4 death cell receptors of Trail: Dr4, Dr5, DcR1, and DcR2.
All proteins except DcR1 and DcR2 had significantly differential expression levels between grade 0 tumors (low malignant potential) and grade 2 and 3 tumors. Trail also showed differential expression between grade 0 tumors and grade 1 tumors. When all tumors were compared, the expression levels of Trail, Dr4, Dr5, DcR1, and Flip differed significantly between early-stage and advanced-stage disease. High Dr5 expression was associated with a poor prognosis in patients who had invasive tumors and in the subgroup of patients who had grade 3 tumors. Furthermore, the combinations of 2 proteins (Trail and Dr5, DcR2 and Cyc, Flip and Dr5, Flip and DcR2, DcR1 and Dr5 or Dr4 and Flip) revealed an association with patient prognosis.
The identification of new proteins in the initial diagnosis and prognosis of patients with epithelial ovarian cancer may lead to a better understanding of the disease, highlighting new potential therapeutic targets, and may be useful in patient management.
在之前的一项微阵列表达分析中,作者鉴定出了在低恶性潜能卵巢肿瘤和侵袭性浆液性上皮性卵巢肿瘤之间差异表达的候选基因。其中,鉴定出了与凋亡相关的候选基因肿瘤坏死因子相关凋亡诱导配体(TRAIL)、半胱天冬酶8(CASP8)、FLICE抑制蛋白(FLIP)和细胞色素C(CYC)。
在本研究中,作者对由235个不同分级和分期的浆液性肿瘤组成的组织芯片进行了免疫组织化学分析,以评估这些候选基因以及TRAIL的4种死亡细胞受体(Dr4、Dr5、DcR1和DcR2)是否存在蛋白表达差异。
除DcR1和DcR2外,所有蛋白在0级肿瘤(低恶性潜能)与2级和3级肿瘤之间均有显著差异表达水平。TRAIL在0级肿瘤和1级肿瘤之间也表现出差异表达。当比较所有肿瘤时,TRAIL、Dr4、Dr5、DcR1和Flip的表达水平在早期和晚期疾病之间存在显著差异。高Dr5表达与侵袭性肿瘤患者以及3级肿瘤患者亚组的不良预后相关。此外,两种蛋白的组合(TRAIL和Dr5、DcR2和CYC、Flip和Dr5、Flip和DcR2、DcR1和Dr5或Dr4和Flip)显示与患者预后相关。
在上皮性卵巢癌患者的初始诊断和预后中鉴定新的蛋白可能有助于更好地理解该疾病,突出新的潜在治疗靶点,并且可能对患者管理有用。